Clinical significance of bone metabolic markers in the diagnosis and treatment of senile osteoporosis

doi:10.3969/j.issn.2095-4344.2015.07.006

Abstract

Abstract:

BACKGROUND: Osteoporosis is not a simple quantitative bone problem. Assessment of osteoporosis is related to age, gender, bone metabolism, bone formation and bone biomechanical dynamics. Tartrate-resistant acid phosphatase 5b (TRACP 5b) and bone alkaline phosphatase (BAP) are two important indicators reflecting bone resorption and bone formation, respectively.

OBJECTIVE: To investigate the clinical significance of bone metabolic markers in the diagnosis and treatment of senile osteoporosis, and to explore its correlation with bone mineral density changes.

METHODS: Totally 100 elderly patients with osteoporosis were enrolled, including 30 cases of 65-70 years old, 40 cases of 71-75 years old, and 30 cases of 76-80 years old. Patients with diabetes, cancers and other bone disorders were excluded. At admission, all patients were measured four bone biochemical markers, including TRACP 5b, BAP, N-terminal midfragment osteocalcin and 25-hydroxyvitamin D. According to the test values of TRACP 5b and BAP, patients were divided into TRACP 5b upregulation group and BAP upregulation group. The correlation of bone mineral density and four biochemical markers with sex and age was analyzed, and intergroup and intragroup differences in four biochemical markers were compared.

RESULTS AND CONCLUSION: The bone mineral densities of the lumbar vertebra and hip were decreased with age (P < 0.05); the bone mineral densities of the lumbar spine and Ward’s triangle in the male patients were higher than those in the female patients. The values of TRACP 5b, BAP, N-terminal midfragment osteocalcin were increased with age (P < 0.05), while the level of 25-hydroxyvitamin D was decreased with age (P < 0.05). Compared with the male patients, the levels of TRACP 5b, BAP and N-terminal midfragment osteocalcin were higher in the female patients, but the level of 25-hydroxyvitamin D was lower in the female patients. After anti-osteoporosis treatment, these four biochemical markers were all improved in the two groups. These findings indicate that the detection of bone metabolic markers contributes to explain whether the main function of osteoblasts or osteoclasts is present in the body, thereby guiding the clinical use of targeted anti-osteoporosis drugs and providing a scientific basis for the clinical treatment and monitoring of osteoporosis.

中国组织工程研究杂志出版内容重点：组织构建；骨细胞；软骨细胞；细胞培养；成纤维细胞；血管内皮细胞；骨质疏松；组织工程

全文链接：

Key words: Osteoporosis, Bone Density, Bone Diseases, Metabolic

CLC Number:

R318

Hu Xiao-jun, Kuang Rong-bin. Clinical significance of bone metabolic markers in the diagnosis and treatment of senile osteoporosis[J]. Chinese Journal of Tissue Engineering Research, 2015, 19(7): 1013-1017.

Figures/Tables 6

References

[1]中华医学会骨质疏松和骨矿盐疾病分会. 原发性骨质疏松症诊治指南(2011年)[J].中华骨质疏松和骨矿盐疾病杂志,2011, 4(3):2-17.
[2]Assessment of fracture risk and its application to screening for post-menopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser. 1994;843:1-129.
[3]Kanis JA, Bianchi G, BilezikianJP,etal.Towards a diagnostic and therapeutic consensus in male osteoporo-sis. Osteoporos Int. 2011;22:2789-98.
[4]Schuit SC, van der Klift M, WeelAE,etal.Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study. Bone. 2004;34:195-202.
[5]张萌萌.骨重建中的骨代谢指标[J].中国骨质疏松杂志,2013,8 (19):866-873.
[6]Gallacher SJ, Dixon T.Impact of treatments for postmenopausal os-teoporosis (Bisphophonates, Parathyroid Hormone, Strontium Ranelate and Denosumab) on bone quality: a systematic review. Calcif Tissue Int. 2010;87: 469-684.
[7]Kanis JA, Johnell O, Oden A,et al. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int. 2008;19:385-97.
[8]Vasikaran S, Eastell R, Bruyère O, et al. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int.2011;22:391-420.
[9]Kanis JA. Diagnosis of osteoporosis and assessment of fracture risk.Lancet.2002, 359:1929-36.
[10]Cosman F, Lindsay R, LeBoffMS,et al. National Osteoporosis Foundation. Clinician’s guide to prevention and treatment of osteoporosis 2013.
[11]Rodrigues AM, Caetano-Lopes J, Vale AC,et al. Low osteocalcin/collagen type I bone gene expression ratio is associ-ated with hip fragility fractures. Bone.2012;51:981-9.
[12]Rodrigues AM, Caetano-Lopes J, Vale AC,etal.Smoking is a predictor of worse trabecular mechanical performance in hip fragility fracture patients. J Bone Miner Metab.2012;30:692-699.
[13]Epstein S.The roles of bone mineral density, bone turnover, and other properties in reducing fracture risk during antiresorptivetherapy. Mayo Clin Proc.2005;80(3):379-388.
[14]Liu Zhonghou. The diagnosis of osteoporosis. Hong Kong:Chinese modern literature and Art Publishing House. 2011:452-465．
[15]Civitelli R, Armamento-Villareal R, Napoli N. Bone turnover markers: un-derstanding their value in clinical trials and clinical practice. Osteoporos Int. 2009;20:843-51.
[16]张萌萌,李亚刚,高远,等.834例女性CTX-1、TRACP、BGP、BALP水平与BMD相关性研究[J].中国骨质疏松杂志, 2012, 18(9): 795-797.
[17]Garnero P, Sornay-Rendu E, Claustrat B,et al. Biochemical markers of bone turnover, endogenous hormones and the risk of frac-tures in postmenopausal women: the OFELY study.J Bone Miner Res.2000;15:1526-1536.
[18]施鸣,范璐,陈新.骨代谢标志物与骨质疏松的相关性研究[J].标记免疫分析与临床,2012,19(6):351-353.
[19]LiuZhonghou. The diagnosis of osteoporosis.Hong Kong: Chinese modern literature and Art Publishing House.2011: 452-465, 520-523.
[20]孟晓林,马东亚,王春,等.注射用骨肽联合阿仑膦酸钠治疗骨质疏松症的临床研究[J].实用药物与临床,2012,1(8):490-491.